Sellas Life Sciences Overview
- Founded
-
2012
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
SLS
- Investments
-
1
- Share Price
-
$1.64
- (As of Friday Closing)
Sellas Life Sciences General Information
Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Contact Information
- Times Square Tower, 7 Times Square
- Suite 2503
- New York, NY 10036
- United States
Sellas Life Sciences Timeline
Sellas Life Sciences Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.64 | $1.71 | $1.17 - $5.58 | $48.2M | 28.3M | 248K | -$1.65 |
Sellas Life Sciences Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 24,293 | 28,276 | 62,423 | 75,277 |
| Revenue | 0 | 1,000 | 7,600 | 1,900 |
| EBITDA | (36,151) | (41,618) | (20,942) | (16,800) |
| Net Income | (35,654) | (41,301) | (20,699) | (16,757) |
| Total Assets | 29,104 | 20,943 | 26,275 | 46,049 |
| Total Debt | 849 | 945 | 808 | 991 |
Sellas Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sellas Life Sciences Comparisons
Industry
Financing
Details
000000
00000
Sellas Life Sciences Competitors (61)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. | |
| 00000 0000000 0000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 0000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Brisbane, CA | 000 | 00000 | 000000000 | 00000 |
Sellas Life Sciences Executive Team (12)
Sellas Life Sciences Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 00000000 0 | Sellas Life Sciences | Chief Executive Officer and President | 000 0000 |
| 00000 0000000000 0 | Sellas Life Sciences | Board Member | 000 0000 |
| 0000 000000 00 | Self | Chairman & Board Member | 000 0000 |
| 0000 000000 | Self | Board Member | 000 0000 |
| 000000 000 0000000 | Self | Board Member | 000 0000 |
Sellas Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Sellas Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sellas Life Sciences Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 29-Dec-2017 | 0000000000 | 0000 | Biotechnology | 0000000 0 |
Sellas Life Sciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
